Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

Journal of Diabetes and its Complications

Volumn 24, Issue 2, 2010, Pages 79-83

  Marfella, Raffaele ^a   Barbieri, Michelangela ^a   Grella, Rodolfo ^a   Rizzo, Maria Rosaria ^a   Nicoletti, Giovanni Francesco ^a   Paolisso, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Dipeptidyl peptidase IV inhibitors; Glicemic control

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SITAGLIPTIN; VILDAGLIPTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADAMANTANE; AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; METFORMIN; MIDDLE AGED; NITRILES; OXIDATIVE STRESS; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 76949098068     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.01.004     Document Type: Article

References (10)

1. Ahrén B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 30 (2007) 1344-1350
2. Drucker D.J., and Nauck M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
3. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., Dietrich B., Golor G., Schrodter A., Keymeulen B., Lasseter K.C., Kipnes M.S., Snyder K., Hilliard D., Tanen M., Cilissen C., De Smet M., de Lepeleire I., Van Dyck K., Wang A.Q., Zeng W., Davies M.J., Tanaka W., Holst J.J., Deacon C.F., Gottesdiener K.M., and Wagner J.A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 91 (2006) 4612-4619
4. Klein R. Hyperglycemia and microvascular disease in diabetes. Diabetes Care 18 (1995) 258-268
5. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Seylan M., Dunning B.E., Deacon C.F., Holst J.J., and Foley J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 90 (2005) 4888-4894
6. Monnier L., Lapinski H., and Colette C. Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 26 (2003) 881-885
7. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., and Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
8. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Taylor W.F., Cremer G.M., and Moxness K.E. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19 (1970) 644-655
9. Service F.J., O'Brien P.C., and Rizza R.A. Measurements of glucose control. Diabetes Care 10 (1987) 225-237
10. Stratton I.M., Alder A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. UK Prospective Diabetes Study Group. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321 (2000) 405-412